About Me

header ads

Sanomics Limited will expand to ASEAN – First Hong Kong biotechnology start-up launched in Thailand

21st December 2018 - Sanomics Limited announced today the launch of a new site located in Bangkok, Thailand. Sanomics (Thailand) Limited’s office and laboratory will be located on the 15th Floor of the Zen Tower, Central World in Bangkok, the central business district of Bangkok. The Grand Opening will take place on 26th January 2019 at Gaysorn Tower. Among distinguished guests Dr Sunny Chai, BBS, Board Chairman of Hong Kong Science and Technology Parks Corporation, Mr Peter Wong, Regional Director for Southeast Asia and South Asia, Hong Kong Trade Development Council, as well as Hong Kong and Thailand renowned leaders in cancer research and management will attend the event.

First Hong Kong biotechnology start-up launched in Thailand

Established in Hong Kong Science and Technology Parks Corporation (HKSTP) in 2015, Sanomics Limited is a Hong Kong based biotechnology start-up that specialises in liquid biopsy and tissue-based genomic diagnostics for cancer patients, so as to help doctors decide personalized cancer solutions for patients. Since 2015, Sanomics’ service covers 20 countries and regions and it has completed more than 7,000 patient cases over the world.

The company is the first Hong Kong biotechnology start-up launched in Thailand after Mrs Carrie Lam, GBM, GBS, Chief Executive of HKSAR’s visit with Prime Minister of Thailand, Mr Prayut Chan-o-cha, in August 2017 to form closer ties between Thailand and Hong Kong.

Thanks to Thailand Government’s “Thailand 4.0” initiative, Sanomics successfully applied for Board of Investment (BOI) company registration with contribution of biotechnology technology transfer in conducting genomic diagnostic in cancer precision medicine, which is the business promoted by BOI.

“Patient First” - Accurate, speedy and affordable genomic diagnostics

“Patient First is our principle. Targeted therapy works only on specific types of tumour growth and requires detailed genetic tests for a doctor to determine if it is applicable. Our mission is to help patients avoid wasting time and money on an ineffective treatment. In Thailand, there are around 123,000 new cancer patients a year. Leveraging Belt and Road Initiative and answering the strong demand of cancer screening tests in Thailand, we have chosen Bangkok to be the first stop of our expansion in ASEAN and we are committed to provide our best service here” said Mr Stanley Sy, CEO of Sanomics Limited.

About Sanomics

The name ‘Sanomics’ is derived from the word of Sanguis, the Latin word for blood, and genomics, which stands for the study of genes. Sanomics’ genomic diagnostics covers both somatic and germline mutations, focusing on lung and women cancer. The company adopts real-time polymerase chain reaction (real time PCR), droplet digital polymerase chain reaction (ddPCR) technology and next generation sequencing (NGS) technology. ddPCR technology significantly enhances diagnostic efficiency while NGS technology is the latest technology that allows the entire genome to be sequenced at once, which provides a much quicker and more economical method for DNA sequencing. To know more about Sanomics: https://www.sanomics.com/